Insider Selling: Establishment Labs (NASDAQ:ESTA) Director Sells 3,575 Shares of Stock

Establishment Labs Holdings Inc. (NASDAQ:ESTA) Director Quiros Juan Jose Chacon sold 3,575 shares of the stock in a transaction that occurred on Wednesday, March 25th. The stock was sold at an average price of $60.08, for a total value of $214,786.00. Following the completion of the transaction, the director owned 1,220,004 shares of the company’s stock, valued at $73,297,840.32. The trade was a 0.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Quiros Juan Jose Chacon also recently made the following trade(s):

• On Monday, March 23rd, Quiros Juan Jose Chacon sold 33,925 shares of Establishment Labs stock. The stock was sold at an average price of $60.39, for a total value of $2,048,730.75.

Establishment Labs Price Performance

NASDAQ:ESTA opened at $55.31 on Friday. Establishment Labs Holdings Inc. has a 52 week low of $26.56 and a 52 week high of $83.31. The stock’s fifty day moving average is $68.98 and its two-hundred day moving average is $61.88. The company has a market capitalization of $1.62 billion, a P/E ratio of -31.79 and a beta of 0.91. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.13. The business had revenue of $64.62 million during the quarter, compared to analysts’ expectations of $63.80 million. Establishment Labs had a negative return on equity of 201.79% and a negative net margin of 24.19%.The company’s revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.19) EPS. Equities analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Investors Weigh In On Establishment Labs

Several institutional investors have recently modified their holdings of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Establishment Labs by 20.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 57,215 shares of the company’s stock valued at $2,335,000 after acquiring an additional 9,557 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Establishment Labs by 1.2% in the second quarter. Geode Capital Management LLC now owns 25,917 shares of the company’s stock valued at $1,105,000 after purchasing an additional 299 shares during the period. SG Americas Securities LLC raised its position in Establishment Labs by 94.2% during the 2nd quarter. SG Americas Securities LLC now owns 8,712 shares of the company’s stock worth $372,000 after buying an additional 4,226 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in Establishment Labs by 0.5% during the second quarter. JPMorgan Chase & Co. now owns 373,112 shares of the company’s stock worth $15,936,000 after purchasing an additional 1,719 shares in the last quarter. Finally, Tejara Capital Ltd raised its stake in shares of Establishment Labs by 39.0% during the 2nd quarter. Tejara Capital Ltd now owns 78,108 shares of the company’s stock worth $3,336,000 after buying an additional 21,898 shares in the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

ESTA has been the subject of a number of recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Citigroup decreased their price objective on shares of Establishment Labs from $81.00 to $74.00 and set a “neutral” rating on the stock in a report on Wednesday, March 11th. BTIG Research lifted their target price on shares of Establishment Labs from $86.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. JPMorgan Chase & Co. boosted their target price on Establishment Labs from $71.00 to $80.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, Mizuho upped their price target on Establishment Labs from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $86.86.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.